Version 1
: Received: 26 June 2023 / Approved: 29 June 2023 / Online: 30 June 2023 (08:14:13 CEST)
How to cite:
Auer, J.; Krotka, P.; Reichard, B.; Traxler, D.; Wendt, R.; Mildner, M.; Ankersmit, H.J.; Graf, A. Selection for Transcatheter versus Surgical Aortic Valve Replacement and Long-term Survival: 10-year Results of the AUTHEARTVISIT Study. Preprints2023, 2023062155. https://doi.org/10.20944/preprints202306.2155.v1
Auer, J.; Krotka, P.; Reichard, B.; Traxler, D.; Wendt, R.; Mildner, M.; Ankersmit, H.J.; Graf, A. Selection for Transcatheter versus Surgical Aortic Valve Replacement and Long-term Survival: 10-year Results of the AUTHEARTVISIT Study. Preprints 2023, 2023062155. https://doi.org/10.20944/preprints202306.2155.v1
Auer, J.; Krotka, P.; Reichard, B.; Traxler, D.; Wendt, R.; Mildner, M.; Ankersmit, H.J.; Graf, A. Selection for Transcatheter versus Surgical Aortic Valve Replacement and Long-term Survival: 10-year Results of the AUTHEARTVISIT Study. Preprints2023, 2023062155. https://doi.org/10.20944/preprints202306.2155.v1
APA Style
Auer, J., Krotka, P., Reichard, B., Traxler, D., Wendt, R., Mildner, M., Ankersmit, H.J., & Graf, A. (2023). Selection for Transcatheter versus Surgical Aortic Valve Replacement and Long-term Survival: 10-year Results of the AUTHEARTVISIT Study. Preprints. https://doi.org/10.20944/preprints202306.2155.v1
Chicago/Turabian Style
Auer, J., Hendrik Jan Ankersmit and Alexandra Graf. 2023 "Selection for Transcatheter versus Surgical Aortic Valve Replacement and Long-term Survival: 10-year Results of the AUTHEARTVISIT Study" Preprints. https://doi.org/10.20944/preprints202306.2155.v1
Abstract
Background Limited data are available from randomized trials comparing outcomes between transcatheter aortic valve replacement (TAVR) and surgery in patients with different risks and with follow-up >2 years. Objective In this large, population-based cohort study, long-term mortality and morbidity were investigated in patients undergoing aortic valve replacement (AVR) for severe aortic stenosis using a surgically implanted bioprosthesis (sB-AVR) or TAVR. Methods Individual data from the Austrian Insurance funds from 2010 through 2020 were analysed. The primary outcome was all-cause mortality, assessed in the overall and propensity score–matched populations. Secondary outcomes included reoperation and cardiovascular events. Results From January 2010 through December 2020, a total of 18 882 patients underwent sB-AVR (n=11 749; 62.2%) or TAVR (n=7133; 37.8%); median follow-up was 4.0 (interquartile range 2.1–6.5) years (maximum 12.3 years). The risk of all-cause mortality was higher with TAVR compared with sB-AVR: hazard ratio (HR) 1.552, 95% confidence interval (CI) 1.469–1.640, p<0.001; propensity score–matched HR 1.510, 1.403–1.625, p<0.001. Estimated median survival was 8.8 years (95% CI 8.6–9.1) with sB-AVR vs 5 years (4.9–5.2) with TAVR. Estimated 5-year survival probability was 0.664 (0.664–0.686) with sB-AVR vs 0.409 (0.378–0.444) with TAVR overall, and 0.690 (0.674–0.707) and 0.560 (0.540–0.582), respectively, with propensity score matching. Other predictors of mortality were age, sex, previous heart failure, diabetes, and chronic kidney disease. Conclusions In >2-year follow-up, selection for TAVR was significantly associated with higher all-cause mortality compared with sB-AVR in patients ≥65 years with severe, symptomatic aortic stenosis.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
